GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Viatris (WBO:MYL) Future 3-5Y EPS without NRI Growth Rate : N/A (As of May. 17, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Viatris Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Viatris's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Viatris's Future 3-5Y EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viatris's Future 3-5Y EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Viatris's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Viatris's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Viatris  (WBO:MYL) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Viatris Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Viatris's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
NBIX LNTH UTHR ELAN ALKS PBH PRGO ALVO AMRX SUPN ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany VIA:Germany VIA:Germany VIA:Germany
Address
1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
Website
https://www.viatris.com
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris Headlines

No Headlines